PortfoliosLab logoPortfoliosLab logo
IDNA vs. LFSC
Performance
Return for Risk
Dividends
Drawdowns
Volatility

Performance

IDNA vs. LFSC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and F/m Emerald Life Sciences Innovation ETF (LFSC). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

IDNA vs. LFSC - Yearly Performance Comparison


Returns By Period

In the year-to-date period, IDNA achieves a 10.92% return, which is significantly higher than LFSC's -4.45% return.


IDNA

1D
4.46%
1M
-6.68%
YTD
10.92%
6M
23.74%
1Y
43.65%
3Y*
8.86%
5Y*
-8.02%
10Y*

LFSC

1D
6.16%
1M
-3.82%
YTD
-4.45%
6M
17.66%
1Y
55.83%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


IDNA vs. LFSC - Expense Ratio Comparison

IDNA has a 0.47% expense ratio, which is lower than LFSC's 0.54% expense ratio.


Return for Risk

IDNA vs. LFSC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDNA
IDNA Risk / Return Rank: 8484
Overall Rank
IDNA Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 8484
Sortino Ratio Rank
IDNA Omega Ratio Rank: 7272
Omega Ratio Rank
IDNA Calmar Ratio Rank: 9292
Calmar Ratio Rank
IDNA Martin Ratio Rank: 8888
Martin Ratio Rank

LFSC
LFSC Risk / Return Rank: 8686
Overall Rank
LFSC Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
LFSC Sortino Ratio Rank: 9090
Sortino Ratio Rank
LFSC Omega Ratio Rank: 8282
Omega Ratio Rank
LFSC Calmar Ratio Rank: 9191
Calmar Ratio Rank
LFSC Martin Ratio Rank: 7979
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDNA vs. LFSC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and F/m Emerald Life Sciences Innovation ETF (LFSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IDNALFSCDifference

Sharpe ratio

Return per unit of total volatility

1.58

1.93

-0.35

Sortino ratio

Return per unit of downside risk

2.21

2.65

-0.44

Omega ratio

Gain probability vs. loss probability

1.26

1.33

-0.07

Calmar ratio

Return relative to maximum drawdown

3.20

3.20

0.00

Martin ratio

Return relative to average drawdown

10.48

8.96

+1.52

IDNA vs. LFSC - Sharpe Ratio Comparison

The current IDNA Sharpe Ratio is 1.58, which is comparable to the LFSC Sharpe Ratio of 1.93. The chart below compares the historical Sharpe Ratios of IDNA and LFSC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


IDNALFSCDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.58

1.93

-0.35

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

0.11

0.94

-0.84

Correlation

The correlation between IDNA and LFSC is 0.72, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


Dividends

IDNA vs. LFSC - Dividend Comparison

IDNA's dividend yield for the trailing twelve months is around 1.06%, while LFSC has not paid dividends to shareholders.


TTM2025202420232022202120202019
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.06%1.18%0.98%1.04%0.54%0.70%0.26%0.80%
LFSC
F/m Emerald Life Sciences Innovation ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

IDNA vs. LFSC - Drawdown Comparison

The maximum IDNA drawdown since its inception was -68.26%, which is greater than LFSC's maximum drawdown of -29.74%. Use the drawdown chart below to compare losses from any high point for IDNA and LFSC.


Loading graphics...

Drawdown Indicators


IDNALFSCDifference

Max Drawdown

Largest peak-to-trough decline

-68.26%

-29.74%

-38.52%

Max Drawdown (1Y)

Largest decline over 1 year

-12.11%

-16.25%

+4.14%

Max Drawdown (5Y)

Largest decline over 5 years

-68.26%

Current Drawdown

Current decline from peak

-45.31%

-11.08%

-34.23%

Average Drawdown

Average peak-to-trough decline

-36.04%

-8.25%

-27.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.83%

5.80%

-1.97%

Volatility

IDNA vs. LFSC - Volatility Comparison

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and F/m Emerald Life Sciences Innovation ETF (LFSC) have volatilities of 10.11% and 10.35%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


IDNALFSCDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.11%

10.35%

-0.24%

Volatility (6M)

Calculated over the trailing 6-month period

18.36%

19.97%

-1.61%

Volatility (1Y)

Calculated over the trailing 1-year period

27.87%

29.24%

-1.37%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

28.53%

29.31%

-0.78%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

29.69%

29.31%

+0.38%